SCHEMBL13304787

SCHEMBL13304787

Bc1cnn2c(NCCC(=O)OCC)cc(-c3ccccc3F)nc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GSK3B P49841 3/20 0.47
▸ CDK2 P24941 5/20 0.46
▸ CCNA2 P20248 1/20 0.42
▸ CCNA1 P78396 1/20 0.42
▸ ADORA2A P29274 5/20 0.41
▸ ADORA1 P30542 4/20 0.41
▸ ADORA3 P0DMS8 4/20 0.41
▸ ADORA2B P29275 1/20 0.41
▸ TOP2A P11388 1/20 0.40
▸ MAPK14 Q16539 1/20 0.37
▸ HPGD P15428 4/20 0.37
▸ KDM4E B2RXH2 3/20 0.37
▸ POLB P06746 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ HSD17B10 Q99714 3/20 0.37
▸ ALDH1A1 P00352 2/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12953525 0.89 GSK3B (0.61) GSK3BCDK2CCNA2CCNA1ADORA2A
SCHEMBL13304958 0.87 GSK3B (0.54) GSK3BCDK2CCNA2CCNA1ADORA2A
SCHEMBL14043294 0.86 GSK3B (0.49) GSK3BCDK2CCNA2CCNA1ADORA2A
SCHEMBL12953851 0.84 GSK3B (0.59) GSK3BCDK2CCNA2CCNA1TOP2A
SCHEMBL12954304 0.83 GSK3B (0.55) GSK3BCDK2CCNA2CCNA1ADORA2A
SCHEMBL14043292 0.83 GSK3B (0.57) GSK3BCDK2CCNA2CCNA1ADORA2A
SCHEMBL13305327 0.80 GSK3B (0.45) GSK3BCDK2CCNA2CCNA1HPGD
SCHEMBL13305701 0.80 GSK3B (0.45) GSK3BCDK2CCNA2CCNA1ADORA2A
SCHEMBL13305019 0.79 GSK3B (0.54) GSK3BCDK2CCNA2CCNA1ADORA2A
SCHEMBL13305409 0.78 GSK3B (0.58) GSK3BCDK2CCNA2CCNA1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1537116-B1 PYRAZOLOPYRIMIDINES SUITABLE FOR THE TREATMENT OF CANCER DISEASES SCHERING CORP (US) 2010-06-02 — — EP disclosed
Send feedback